Chiappetta Nicole, Steier James, Gruber Barry
Department of Rheumatology, Stony Brook University Hospital, Stony Brook, New York 11794, USA.
J Clin Rheumatol. 2005 Oct;11(5):264-6. doi: 10.1097/01.rhu.0000182155.08982.60.
Dermatomyositis is an inflammatory myopathy characterized by muscle weakness and inflammation. In contrast to polymyositis and inclusion body myositis, humoral immune mechanisms appear to contribute to the pathogenesis of dermatomyositis. A 56-year-old man with dermatomyositis resistant to conventional therapies was treated with 6 weekly infusions of the anti-CD-20 monoclonal antibody, rituximab, at a dosage of 100 mg/m in addition to other agents. The patient demonstrated a remarkable clinical response as indicated by an increase in muscle strength and a decline in creatine kinase enzymes. B-cell depletion therapy with rituximab used alone or in combination with other immunosuppressive therapies may be a viable option in patients with dermatomyositis as well as other autoimmune diseases refractory to current therapies.
皮肌炎是一种以肌肉无力和炎症为特征的炎性肌病。与多发性肌炎和包涵体肌炎不同，体液免疫机制似乎在皮肌炎的发病机制中起作用。一名56岁对传统疗法耐药的皮肌炎男性患者，除使用其他药物外，每周接受6次抗CD-20单克隆抗体利妥昔单抗静脉输注治疗，剂量为100 mg/m²。患者表现出显著的临床反应，肌肉力量增加，肌酸激酶水平下降。单独使用利妥昔单抗或与其他免疫抑制疗法联合使用进行B细胞清除疗法，对于皮肌炎患者以及对当前疗法难治的其他自身免疫性疾病患者可能是一种可行的选择。
